Brain natriuretic peptide: diagnostic and prognostic value in chronic heart failure (a literature review)
DOI:
https://doi.org/10.14739/2310-1210.2024.3.297277Keywords:
brain natriuretic peptide, heart failure, diagnosis, prognosisAbstract
The increase in the prevalence of cardiovascular disease has caused a rapid increase in the risk of developing heart failure. For many years, chronic heart failure (CHF) has occupied one of the leading positions in the structure of cardiac and all-cause mortality worldwide, resulting in not only negative social, but also economic effects. To optimize the timely detection of this pathological condition, laboratory biomarker-based diagnostics of heart dysfunction is widely used along with echocardiographic examination. Brain natriuretic peptide (BNP) is currently considered one of the most well-known and informative biochemical markers in heart failure.
The aim of the work was to cover the results of current scientific research according to the principles of evidence-based medicine regarding the use of BNP and its precursor NT-proBNP for the diagnosis of CHF, prognosis and monitoring of the treatment effectiveness. To achieve this goal, an analysis of literary sources published in scientometric databases such as ScienceDirect, Web of Science, Google Scholar, PubMed, Scopus for the period 2013–2024 was carried out.
Conclusions. BNP and NT-proBNP have been found to be informative markers for the early diagnosis of chronic heart failure and can also be recommended for dynamic assessment of patients’ condition and the effectiveness of their treatment. It is proposed to continue the research on clarifying the threshold diagnostic levels of the biomarkers in patients with chronic heart failure and comorbid conditions such as type 2 diabetes mellitus, obesity, as well as in consideration of their sex, age, racial and ethnic characteristics, which in the future would promote the optimization of timely diagnosis, selection of appropriate treatment and improvement of further prognosis.
References
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi: https://doi.org/10.1161/CIR.0000000000001063
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: https://doi.org/10.1093/eurheartj/ehab368
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi: https://doi.org/10.1093/eurheartj/ehad195
Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(8):935-44. doi: https://doi.org/10.1016/j.jacc.2018.11.049
Ferrannini G, Benson L, Lautsch D, Dahlström U, Lund LH, Savarese G, et al. N-terminal pro-B-type natriuretic peptide concentrations, testing and associations with worsening heart failure events. ESC Heart Fail. 2023 Dec 19. doi: https://doi.org/10.1002/ehf2.14613
Voronkov LG, Berezin OE, Zharinova VY, Zebel VM, Koval OA, Rudik YS, et al. [Biological markers and their use in heart failure. Consensus of the All-Ukrainian Association of Cardiologists of Ukraine, All-Ukrainian Association of Specialists in Cardiac Failure, and the Ukrainian Association of Specialists in Emergency Cardiology]. Ukrainskyi kardiolohichnyi zhurnal. 2019;26(2):19-30. Ukrainian. doi: https://doi.org/10.31928/1608-635X-2019.2.1122
Koval OA. [Early laboratory diagnosis and monitoring of the course of heart failure: changing modern approaches is the key to effective treatment and improved prognosis]. Zdorovia Ukrainy. 2022;(3-4):6-7. Ukrainian. Available from: https://health-ua.com/multimedia/userfiles/files/2022/Cardio_3-4_2022/Cardio_3-4_2022_st6.pdf
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15. doi: https://doi.org/10.21037/amj.2020.03.03
Cleland JG, van Veldhuisen DJ, Ponikowski P. The year in cardiology 2018: heart failure. Eur Heart J. 2019;40(8):651-61. doi: https://doi.org/10.1093/eurheartj/ehz010
Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572-80. doi: https://doi.org/10.1016/S0140-6736(17)32520-5
Krech R, Kickbusch I, Franz C, Wells N. Banking for health: the role of financial sector actors in investing in global health. BMJ Glob Health. 2018;3(Suppl 1):e000597. doi: https://doi.org/10.1136/bmjgh-2017-000597
Emdin CA, Conrad N, Kiran A, Salimi-Khorshidi G, Woodward M, Anderson SG, et al. Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart. 2017;103(1):55-62. doi: https://doi.org/10.1136/heartjnl-2016-309706
Díez J, Butler J. Growing Heart Failure Burden of Hypertensive Heart Disease: A Call to Action. Hypertension. 2023;80(1):13-21. doi: https://doi.org/10.1161/HYPERTENSIONAHA.122.19373
Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541-9. doi: https://doi.org/10.1016/j.jacc.2014.05.030
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-88. doi: https://doi.org/10.1161/CIRCULATIONAHA.114.010389
Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339-51. doi: https://doi.org/10.1016/j.jacc.2017.11.019
Grigorescu ED, Lacatusu CM, Floria M, Mihai BM, Cretu I, Sorodoc L. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives. Diagnostics. 2019;9(3):121. doi: https://doi.org/https://doi.org/10.3390/diagnostics9030121
Antoniuk YO, Gumeniuk AF, Sakovych OO, Zhebel VM. The role of the brain natriuretic peptide gene polymorphism in the diagnostic use of the biomarker in myocardial dysfunction in men, residents of Podillya with comorbid essential hypertension and type 2 diabetes mellitus. Biomedical and Biosocial Anthropology. 2020;(38):54-60. doi: https://doi.org/10.31393/bba38-2020-08
Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18-25. doi: https://doi.org/10.1016/j.peptides.2018.05.012
Tan ES, Chan SP, Liew OW, Chong JP, Gerard Leong KT, Daniel Yeo PS, et al. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure. JACC Heart Fail. 2024;12(3):461-74. doi: https://doi.org/10.1016/j.jchf.2023.09.011
Tanase DM, Radu S, Al Shurbaji S, Baroi GL, Florida Costea C, Turliuc MD, et al. Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. Int J Mol Sci. 2019;20(11):2629. doi: https://doi.org/10.3390/ijms20112629
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JG, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. doi: https://doi.org/10.1002/ejhf.1494
Taylor CJ, Ordóñez-Mena JM, Lay-Flurrie SL, Goyder CR, Taylor KS, Jones NR, et al. Natriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study. Br J Gen Pract. 2022;73(726):e1-e8. doi: https://doi.org/10.3399/BJGP.2022.0278
Novack ML, Zevitz ME. Natriuretic Peptide B Type Test [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556136/
Christopherson K, Kobeissi MM. Applying Evidence-Based Practice Guidelines in Primary Care: A Heart Failure Scenario. The Journal for Nurse Practitioners. 2024;20(1):104878. doi: https://doi.org/10.1016/j.nurpra.2023.104878
Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020;13(2):e006541. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.119.006541
Roalfe AK, Lay-Flurrie SL, Ordóñez-Mena JM, Goyder CR, Jones NR, Hobbs FD, et al. Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study. Eur Heart J. 2021;43(9):881-91. doi: https://doi.org/10.1093/eurheartj/ehab781
Jehn S, Mahabadi AA, Pfohl C, Vogel L, Fadi Al-Rashid, Luedike P, et al. BNP and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure. JACC. 20231;2(10):100688. doi: https://doi.org/10.1016/j.jacadv.2023.100688
Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-35. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.024593
Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8(3):e58287. doi: https://doi.org/10.1371/journal.pone.0058287
Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35(23):1559-67. doi: https://doi.org/10.1093/eurheartj/ehu090
Davarzani N, Sanders-van Wijk S, Karel J, Maeder MT, Leibundgut G, Gutmann M, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. J Card Fail. 2017;23(5):382-9. doi: https://doi.org/10.1016/j.cardfail.2017.02.001
Senni M, Lopez-Sendon J, Cohen-Solal A, Ponikowski P, Nkulikiyinka R, Freitas C, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail. 2022;9(6):3791-803. doi: https://doi.org/10.1002/ehf2.14050
Simioniuc A, Carluccio E, Ghio S, Rossi A, Biagioli P, Reboldi G, et al. Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients. Int J Cardiol. 2016;224:416-23. doi: https://doi.org/10.1016/j.ijcard.2016.09.034
Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC Heart Fail. 2020;8(11):931-9. doi: https://doi.org/10.1016/j.jchf.2020.08.008
Karlström P, Johansson P, Dahlström U, Boman K, Alehagen U. Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. BMC Cardiovasc Disord. 2016;16:39. doi: https://doi.org/10.1186/s12872-016-0221-7
Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacol Ther. 2021;227:107863. doi: https://doi.org/10.1016/j.pharmthera.2021.107863
Werhahn SM, Becker C, Mende M, Haarmann H, Nolte K, Laufs U, et al. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Fail. 2022;9(1):100-9. doi: https://doi.org/10.1002/ehf2.13703
Dhinakaran K, Selvarajan N. Correlation of NT-proBNP levels with clinical and echocardiographic features in evaluation of patients admitted with heart failure. Journal of Medical and Scientific Research. 2023;11(4):275-9. doi: https://doi.org/10.17727/jmsr.2023/11-51
Kajikawa Y, Ueda A, Ikeda M, Hirota M. Estimation of brain natriuretic peptide values from N-terminal pro brain natriuretic peptide levels and other factors. European Heart Journal. 2023;44(Suppl 1). doi: https://doi.org/10.1093/eurheartj/ehac779.044
Schupp T, Abumayyaleh M, Weidner K, Lau F, Schmitt A, Reinhardt M, et al. Diagnostic and Prognostic Value of Aminoterminal Prohormone of Brain Natriuretic Peptide in Heart Failure with Mildly Reduced Ejection Fraction Stratified by the Degree of Renal Dysfunction. J Clin Med. 2024;13(2):489. doi: https://doi.org/10.3390/jcm13020489
Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141(12):1001-26. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.041886
Shi K, Zhang G, Fu H, Li XM, Yu SQ, Shi R, et al. Reduced thoracic skeletal muscle size is associated with adverse outcomes in diabetes patients with heart failure and reduced ejection fraction: quantitative analysis of sarcopenia by using cardiac MRI. Cardiovasc Diabetol. 2024;23(1):28. doi: https://doi.org/10.1186/s12933-023-02109-7
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi: https://doi.org/10.1093/eurheartj/ehz486
Åkerblom A, Wojdyla D, Steg PG, Wallentin L, James SK, Budaj A, et al. Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. J Thromb Thrombolysis. 2019;48(4):563-9. doi: https://doi.org/10.1007/s11239-019-01938-2
Berezin AE, Berezin AA. Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review. Diabetes Ther. 2020;11(6):1271-91. doi: https://doi.org/10.1007/s13300-020-00835-9
Palau P, Bertomeu-González V, Sanchis J, Soler M, de la Espriella R, Domínguez E, et al. Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction. Rev Esp Cardiol (Engl Ed). 2020;73(6):463-70. English, Spanish. doi: https://doi.org/10.1016/j.rec.2019.09.002
Belovol AN, Bobronnikova LR, Al’-Trawneh OV. [Pathogenetic features of the combined course of arterial hypertension and diabetes mellitus 2 type]. Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini. 2017;(1):4-9. Russian. doi: https://doi.org/10.15407/internalmed2017.01.004
Brutsaert EF, Biggs ML, Delaney JA, Djoussé L, Gottdiener JS, Ix JH, et al. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study. Metabolism. 2016;65(10):1489-97. doi: https://doi.org/10.1016/j.metabol.2016.06.002
Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294-e324. doi: https://doi.org/10.1161/CIR.0000000000000691
Vinnakota S, Chen HH. The Importance of Natriuretic Peptides in Cardiometabolic Diseases. J Endocr Soc. 2020;4(6):bvaa052. doi: https://doi.org/10.1210/jendso/bvaa052
Gupta DK, Walford GA, Ma Y, Jarolim P, Wang TJ; DPP Research Group. Racial/ethnic differences in circulating natriuretic peptide levels: The Diabetes Prevention Program. PLoS One. 2020;15(2):e0229280. doi: https://doi.org/10.1371/journal.pone.0229280
Birukov A, Eichelmann F, Kuxhaus O, Polemiti E, Fritsche A, Wirth J, et al. Opposing Associations of NT-proBNP With Risks of Diabetes and Diabetes-Related Complications. Diabetes Care. 2020;43(12):2930-7. doi: https://doi.org/10.2337/dc20-0553
Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21(1):40-9. doi: https://doi.org/10.1002/ejhf.1359
Chong VH, Singh JS, Dow E, McCrimmon RJ, Lang CC, Struthers AD. Using biomarkers to identify diabetic patients with multiple silent cardiac abnormalities. European Heart Journal. 2020;41(Suppl 2): ehaa946.2942. doi: https://doi.org/10.1093/ehjci/ehaa946.2942
Antoniuk YO, Humeniuk AF, Pashkova YP, Sakovych OO, Zhebel VM. [The diagnostic value of brain natriuretic peptide in men with comorbid essential arterial hypertension and type 2 diabetes mellitus]. Zaporozhye medical journal. 2020;22(5):627-36. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2020.5.214729
Clerico A, Masotti S, Musetti V, Passino C. Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. J Lab Precis Med. 2019;4:8. doi: https://doi.org/10.21037/jlpm.2019.01.03
Kim HL, Kim MA, Choi DJ, Han S, Jeon ES, Cho MC, et al. Gender difference in the prognostic value of N-Terminal Pro-B type natriuretic peptide in patients with heart failure - a report from the korean heart failure registry (KorHF). Circulation Journal. 2017;81(9):1329-36. doi: https://doi.org/10.1253/circj.CJ-16-1345
Sursaieva LM, Zhebel VM, Pashkova YP, Kulchevich LV, Shevchuk OK. [BNP: phenotypic features of plasma concentration of biomarkers through the prism of sexual dimorphism]. Reports of Vinnytsia National Medical University. 2020;24(4):571-6. Ukrainian. doi: https://doi.org/10.31393/reports-vnmedical-2020-24(4)-02
Romiti GF, Recchia F, Zito A, Visioli G, Basili S, Raparelli V. Sex and Gender-Related Issues in Heart Failure. Heart Fail Clin. 2020;16(1):121-30. doi: https://doi.org/10.1016/j.hfc.2019.08.005
Sobhani K, Nieves Castro DK, Fu Q, Gottlieb RA, Van Eyk JE, Noel Bairey Merz C. Sex differences in ischemic heart disease and heart failure biomarkers. Biol Sex Differ. 2018;9(1):43. doi: https://doi.org/10.1186/s13293-018-0201-y
Gupta DK, Daniels LB, Cheng S, deFilippi CR, Criqui MH, Maisel AS, et al. Differences in Natriuretic Peptide Levels by Race/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2017;120(6):1008-15. doi: https://doi.org/10.1016/j.amjcard.2017.06.030
Bajaj NS, Gutiérrez OM, Arora G, Judd SE, Patel N, Bennett A, et al. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018;3(1):11-7. doi: https://doi.org/10.1001/jamacardio.2017.4207
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
